We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.40 | 2.30 | 2.50 | 2.40 | 2.40 | 2.40 | 14,156 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0095 | -2.53 | 13.04M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/11/2024 08:45 | More importantly, it's up on much higher volume.Bodes very well. | premium beeks | |
13/11/2024 08:45 | SEA about to fly | smraynot | |
13/11/2024 08:44 | Buckle up bulls | atmysignal | |
13/11/2024 08:41 | High tight flag? | hazl | |
13/11/2024 08:38 | I expect it will be in play most of the day. IMO | hazl | |
13/11/2024 08:32 | 'Why do we need to use Genedrive? Babies admitted to the TMBU often need antibiotics. One antibiotic we use is called Gentamicin, which is a drug belonging to a family of antibiotics called Aminoglycosides. Gentamicin can sometimes lead to kidney or hearing problems, but side-effects are relatively uncommon, so Gentamicin has remained one of our first-choice antibiotics because it works well and has low antibiotic resistance. Low antibiotic resistance means that germs are less likely to build up a resistance to antibiotics in the future. However, one in 500 people have a genetic variation (a difference in their DNA) that can put them at higher risk of side effects from Gentamicin. For people who have this genetic variation, even a single dose can sometimes cause severe hearing loss that cannot be cured.' Same source as above. | hazl | |
13/11/2024 08:26 | POLX Polarean Imaging about to break out above 2p soon. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 155p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. | m_night10 | |
13/11/2024 08:18 | And batiatus quiet is the biggest bonus lolm | bones698 | |
13/11/2024 08:06 | 2.5 and really going!!!! | billthebank | |
13/11/2024 07:47 | Genedrive a company that's actually good for society. Caught the Government's attention too. | hazl | |
13/11/2024 06:33 | Now that we are included in the Government's list and are being used in NHS locations, we are having our validity heralded. This has been endorsed at the top for success, it seems. Let's hope we are not taken out too cheaply before then! *Genedrive featured in UK Department for Business & Trade's genomics spotlight'. | hazl | |
12/11/2024 23:38 | Your flogging a dead horse now batiatus . Enjoy watching the rise tomorrow and we will enjoy the silence again . Idiot | bones698 | |
12/11/2024 22:31 | One thing for sure is that the share price has been on a downtrend. From £2 to 5p, and from 5p to now 2p. The companies fundamentals have not changed one bit. Monthly cash burn is still £400-600K. There have been no other sales besides the £100K 9 months ago. The directors cannot expect to sit around all day taking a salary without providing any value to shareholders. They need to prove the kits can sell and start making some profit. As things stand, it's just a weeks after weeks without sales, only cash burn. The only thing that is coming is a fundraise. (G)enuinely (D)on't (R)ecommend | batiatus | |
12/11/2024 20:24 | You obviously didn't watch the rise upto 5p . Another Muppet | bones698 | |
12/11/2024 19:59 | Up one day down the next | muttznutz1953 | |
12/11/2024 19:56 | What do you call small batty, apart from your tiny brain of courseWe've had 40% swings here for weeks, what more do you want?What a foreskin. | premium beeks |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions